Details for New Drug Application (NDA): 022118

✉ Email this page to a colleague

NDA 022118 describes FENOGLIDE, which is a drug marketed by Salix and is included in one NDA. It is available from two suppliers. There are four patents protecting this drug and one Paragraph IV challenge. Additional details are available on the FENOGLIDE profile page.

The generic ingredient in FENOGLIDE is fenofibrate. There are forty-two drug master file entries for this compound. Fifty-four suppliers are listed for this compound. Additional details are available on the fenofibrate profile page.

Summary for 022118

Tradename:	FENOGLIDE
Applicant:	Salix
Ingredient:	fenofibrate
Patents:	4

Pharmacology for NDA: 022118

Medical Subject Heading (MeSH) Categories for 022118

Hypolipidemic Agents

Suppliers and Packaging for NDA: 022118

Tradename	Generic Name	Dosage	NDA	Application Type	Supplier	National Drug Code	Package Code	Package
FENOGLIDE	fenofibrate	TABLET;ORAL	022118	NDA	Santarus, Inc.	68012-490	68012-490-90	90 TABLET in 1 BOTTLE (68012-490-90)
FENOGLIDE	fenofibrate	TABLET;ORAL	022118	NDA	Santarus, Inc.	68012-495	68012-495-07	6 BOTTLE in 1 BOX (68012-495-07) / 7 TABLET in 1 BOTTLE

Profile for product number 001

Active Rx/OTC/Discontinued:	DISCN	Dosage:	TABLET;ORAL			Strength	40MG
Approval Date:	Aug 10, 2007	TE:		RLD:	Yes
Patent:	⤷ Sign Up	Patent Expiration:	Dec 9, 2024	Product Flag?	Y	Substance Flag?		Delist Request?
Patent:	⤷ Sign Up	Patent Expiration:	Oct 1, 2024	Product Flag?	Y	Substance Flag?		Delist Request?
Patented Use:	FOR REDUCING TOTAL CHOLESTEROL (TOTAL-C), LDL-C, APO-LIPOPROTEIN B, OR TOTAL TRIGLYCERIDES, AND TREATING HYPERTRIGLYCERIDEMIA
Patent:	⤷ Sign Up	Patent Expiration:	Oct 1, 2024	Product Flag?	Y	Substance Flag?		Delist Request?
Patented Use:	USE OF FENOFIBRATE FOR REDUCING ELEVATED TOTAL CHOLESTEROL (TOTAL-C), LDL-C, APO-LIPOPROTEIN B, OR TOTAL TRIGLYCERIDES

Expired US Patents for NDA 022118

Subscribe to access the full database, or Sign Up
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Salix	FENOGLIDE	fenofibrate	TABLET;ORAL	022118-001	Aug 10, 2007	⤷ Sign Up	⤷ Sign Up
Salix	FENOGLIDE	fenofibrate	TABLET;ORAL	022118-002	Aug 10, 2007	⤷ Sign Up	⤷ Sign Up
Salix	FENOGLIDE	fenofibrate	TABLET;ORAL	022118-002	Aug 10, 2007	⤷ Sign Up	⤷ Sign Up
Salix	FENOGLIDE	fenofibrate	TABLET;ORAL	022118-001	Aug 10, 2007	⤷ Sign Up	⤷ Sign Up
Salix	FENOGLIDE	fenofibrate	TABLET;ORAL	022118-001	Aug 10, 2007	⤷ Sign Up	⤷ Sign Up
Salix	FENOGLIDE	fenofibrate	TABLET;ORAL	022118-002	Aug 10, 2007	⤷ Sign Up	⤷ Sign Up
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>Patent No.	>Patent Expiration

Complete Access Available with Subscription

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.